1379P Margetuximab (M) with retifanlimab (R) in HER2+, PD-L1+ 1st-line unresectable/metastatic gastroesophageal adenocarcinoma (GEA): MAHOGANY cohort A
Daniel V.T. Catenacci(University of Chicago), Y-K. Kang(Asan Medical Center), Kyung-Woo Lee(Konkuk University), H. Park(Washington University in St. Louis), Alexander I. Spira(Virginia Cancer Specialists), Susanna V. Ulahannan(Oklahoma State University Oklahoma City), Mohamad Bassam Sonbol(WinnMed), S.J. Klempner(Massachusetts General Hospital), Patrick M. Boland(Roswell Park Comprehensive Cancer Center), Eric J. Avery(Nebraska Hematology-Oncology), Sang Cheul Oh(Korea University), Julio A. Peguero(Hematology Oncology Consultants), Hyun Cheol Chung(Yonsei University), Jichao Sun(MacroGenics (United States)), S.T. Kim(Samsung Medical Center), F. Gardner(Florida Cancer Specialists & Research Institute), Minori Koshiji Rosales(MacroGenics (United States)), Joseph Chao(Amgen (United States)), D-Y. Oh(Seoul National University Hospital), Byoung Yong Shim(The Catholic University of Korea St. Vincent's Hospital)
Cited by 14
Related Papers
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C Mutation
|New England Journal of Medicine|2021|1.8k